ArticleNutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition2026
Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study.
Article in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
methodsPatients with aPC who were referred to a dietitian for suspected PEI at the Cross Cancer Institute (Edmonton, Canada) were enrolled. Baseline (BL) PEI symptoms were evaluated prior to PERT initiation; dose was optimized by 1 month. PEI symptom severity was assessed with the Pancreatic Enzyme Insufficiency Questionnaire (PEI-Q) at BL, reassessed after 1 and 3 months, and compared between BL and first reassessment. Mean weight change from BL to 1 month (percentage per 30 days) was compared with change from 1 to 3 months. Continuous and categorical variables were compared using paired samples t tests and McNemar test, respectively.
resultsOf 29 patients enrolled, 23 initiated PERT and completed ≥1 symptom reassessment. Median reported PERT dose at reassessment was 200,000 USP lipase units/day (IQR 97,200, 300,000). Improvements in mean severity scores for stomach pain (P = 0.001) bloating (P = 0.049) and stomach noises (P = 0.032) were reported at reassessment, with a trend toward improved appetite (P = 0.053). Prevalence of moderate/severe PEI decreased (11/23 vs 4/23, P = 0.020). Weight loss slowed after 1 month (-4.3 ± 4.8%/30 days [BL to 1 month] vs -0.2 ± 3.9%/30 days, P = 0.033).
conclusionPatients receiving dietitian-directed PERT showed improved abdominal symptoms and attenuated weight loss after dose optimization, addressing a patient priority for those with aPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.